AstraZenca has entered into a settlement agreement with Accord Health and Intas Pharmaceuticals to prevent the sale of generic copies of its anti-psychotic drug Seroquel XR in the US.

The company has granted Accord a licence to enter the US market with its version of the drug on November 1 2016, or earlier, depending upon certain circumstances.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The news follows last week’s announcement that AZ had won its fight to prevent Handa Pharmaceuticals from entering the market with its copy of the extended-release pill for the treatment of schizophrenia until 2016.

The news does not resolve patent battles with other generic drugmakers.

Seroquel will lose patent protection next year but AZ is trying to switch patients over to the newer version (Seroquel XR) ahead of the arrival of generic forms of basic Seroquel.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now